74252-25-8
74252-25-8 结构式
基本信息
吲哚美锌钠
水溶性吲哚美辛
吲哚美辛钠 水溶性
吲哚美辛钠盐三水合物
吲哚美辛钠中文名称:吲哚美辛钠中文同义词:吲哚美辛钠
2-甲基-1-(4-氯苯甲酰基)-5-甲氧基-1H-吲哚-3-乙酸钠
INDOMETHACIN SODIUM SALT TRIHYDRATE英文同义词:SODIUM,2-[1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOL-3-YL]ACETATE,TRIHYDRATE
INDOMETACIN FARNESIL
Sodium salt trihydrate
Indomethacin sodium hydrate
Indomethacin sodium trihydrate
Indomethacin sodium salt 3-hydrate
INDOMETHACIN SODIUM SALT TRIHYDRATE
sodium,2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate,trihydrate
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, sodi um salt, trihydrate
1H-Indole-3-aceticacid, 1-(4-chlorobenzoyl)-5-Methoxy-2-Methyl-, sodiuM salt, hydrate (1:1:3)
物理化学性质
常见问题列表
| Target | Value |
|
COX1
() | 0.11 μM |
|
COX2
() | 0.78 μM |
Indomethacin is a potent and nonselective inhibitor of COX1 and COX2 , with IC 50 s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin inhibits lipopolysaccharide (LPS)-induced PGE2 production (COX-2) in a human whole blood assay with a potency (IC 50 =0.68±0.17 μM), and suppresses coagulation-induced TXB2 production (COX-1) (IC 50 =0.19±0.02 μM). Indomethacin blocks COX-1 with an IC 50 of 20±1 nM in U937 cell microsomes at a low arachidonic acid concentration (0.1 μM).
Indomethacin dose-dependently inhibits both the carrageenan-induced rat paw oedema (ED 50 , 2.0 mg/kg), hyperalgesia (ED 50 , 1.5 mg/kg), and is also effective at reversing LPS-induced pyrexia in rats (ED 50 , 1.1 mg/kg). Indomethacin (2.5 mg/kg, i.p) decreases the number of NeuN + cells in the animals at 8 days after ET-1 injection. Indomethacin also reduces microglia/macrophage activation at 14 days. Indomethacin significantly increases the number of SVZ DCX + cells/field at 14 days post stroke. Indomethacin (22.9 mg/kg, p.o.) produces 8 to 10 linear mucosal lesions extended from the fundic to pyloric area of stomach wall.